Last reviewed · How we verify
Cisplatine
Cisplatine is a Small molecule drug developed by Lymphoma Study Association. It is currently in Phase 3 development.
Cisplatin is a chemotherapy medication used to treat various types of cancer, including head and neck cancer, non-small-cell lung carcinoma, penile cancer, and squamous carcinoma. It is a small molecule DNA inhibitor that works by interfering with DNA, classified as an INHIBITOR drug.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cisplatine |
|---|---|
| Sponsor | Lymphoma Study Association |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer (PHASE3)
- Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT (PHASE3)
- Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma (PHASE2)
- PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma (PHASE2)
- Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis (PHASE2)
- Basal Tumours in Bladder Cancer, Response to chemoTherapy
- A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatine CI brief — competitive landscape report
- Cisplatine updates RSS · CI watch RSS
- Lymphoma Study Association portfolio CI
Frequently asked questions about Cisplatine
What is Cisplatine?
Who makes Cisplatine?
What development phase is Cisplatine in?
Related
- Manufacturer: Lymphoma Study Association — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing